Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Haleon Plc (LSE/NYSE: HLN) covers the month of March 2026, with a specific reporting date of March 13, 2026. The document serves as a notification and public disclosure under the UK Market Abuse Regulation regarding transactions by Persons Discharging Managerial Responsibilities (PDMRs). Haleon operates as a consumer health company with a portfolio spanning Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a regulatory disclosure of equity compensation grants. The only quantitative data provided relates to the volume of share awards granted to executives:
- CEO (Brian McNamara): Total of 1,813,680 shares granted (1,639,855 under Performance Share Plan; 173,825 under Deferred Annual Bonus Plan).
- CFO (Dawn Allen): Total of 808,297 shares granted (712,784 under Performance Share Plan; 95,513 under Deferred Annual Bonus Plan).
- Transaction Price: Nil (conditional awards).
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details the initial notification of new share award grants made on March 12, 2026, outside of a trading venue. These grants are subject to performance conditions over a period ending December 31, 2028, and include malus and clawback provisions.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on market outlook, or specific risk factors. It references that performance targets for the share plans are disclosed in the 2025 Annual Report and Form 20-F. The awards are made in accordance with the Directors' Remuneration Policy.
Investor Verification Checklist
- Verify the specific performance conditions and targets for the 2026-2028 period in the 2025 Annual Report and Form 20-F.
- Confirm the vesting schedule and any additional terms for the Deferred Annual Bonus Plan awards.
- Review the Directors' Remuneration Policy to understand the malus and clawback provisions applicable to these grants.
- Note that this filing contains no operational or financial results; refer to quarterly or annual reports for those metrics.